Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183738 | PMC |
| http://dx.doi.org/10.1097/CM9.0000000000001434 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.
Neurooncol Adv
November 2024
Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor survival rates despite current treatments. The standard of care (SOC) includes surgery, followed by radiotherapy plus concurrent and adjuvant chemotherapy with temozolomide (TMZ). This phase II trial assessed the safety and efficacy of neoadjuvant TMZ (nTMZ) before and during chemoradiotherapy in newly diagnosed GBM patients.
View Article and Find Full Text PDFImpact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
J Neurooncol
October 2024
Department of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Article Synopsis
- Oligodendroglioma is a brain tumor characterized by specific genetic mutations and treatments typically involve surgery followed by either observational care or a combination of radiation and chemotherapy.
- This study analyzed data from 277 patients with IDH-mutant, 1p/19q codeleted oligodendrogliomas to examine the impact of different adjuvant treatment regimens on progression-free survival (PFS).
- Results indicated that patients with grade 3 tumors showed significantly longer PFS when treated with radiation and PCV chemotherapy compared to those receiving radiation with TMZ or no adjuvant therapy, emphasizing the need for more research in this area.
Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAF glioblastoma results in sustained response: A case report.
Neurooncol Adv
July 2024
Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Saint Monica, California, USA.
Radiation's confounding and adverse effects on tumor microenvironment and normal brain could potentially be delayed by upfront combination treatment. We present a patient with newly diagnosed -mutant, PD-L1-positive glioblastoma treated with off-label RAF/MEK inhibitors encorafenib/binimetinib after progressing on postoperative immune checkpoint blockade and temozolomide (no radiation administered: NCT03425292). Complete response occurred 6 months after adding encorafenib/binimetinib, and clinical benefit was sustained for over 20 months.
View Article and Find Full Text PDFSequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.
J Clin Med
April 2024
Department of Medical or Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Article Synopsis
- The study aimed to determine the best treatment sequence for patients with advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) by analyzing data on progression-free survival (PFS) and overall survival (OS).
- In total, 201 patients were examined, revealing that those with grade 1 pNETs, prior tumor surgery, and those treated with radioligand therapy (RLT) experienced significantly longer PFS.
- The findings suggest that RLT is associated with better PFS than other treatments, and that a treatment sequence starting with somatostatin analogs (SSA) followed by RLT leads to improved outcomes.
Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors.
Neurooncol Adv
December 2023
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas originating from cellular components within the nerve sheath. The incidence of MPNST is highest in people with neurofibromatosis type 1 (NF1), and MPNST is the leading cause of death for these individuals. Complete surgical resection is the only curative therapeutic option, but is often unfeasible due to tumor location, size, or presence of metastases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!